
© 2025 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
83,40 | 83,50 | 11:27 | |
83,40 | 83,50 | 11:27 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | Jim Cramer on Merck & Co., Inc. (MRK): 'Drug Stocks Are Really Getting Hurt' | ||
Di | Merck Announces Health Canada Approval For KEYTRUDA | KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II... ► Artikel lesen | |
Di | Health Canada Approves Merck's KEYTRUDA (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatmen | ||
Di | Merck stock price target lowered to $95 by Bernstein SocGen | ||
Mo | Merck cut to hold by TD Cowen, impending Keytruda LOE cited |